ESMO 2026 | ADC structure and toxicity: what oncologists need to know
Yeon Hee Park, MD, Samsung Medical Center, Seoul, South Korea, comments on the evolution and clinical significance of antibody-drug conjugates (ADCs) in oncology, noting that since their initial development in 2000, ADCs have become a cornerstone of treatment for both solid and hematologic tumors over the past two decades. Comprehensive knowledge of ADC structure and toxicity determinants is critical for all oncologists involved in patient management. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
so now it’s the era of ADC. Since the first developed ADC in 2000, and then already it passed 20 more years, during that time, ADC is a kind of a backbone of treatment for solid tumor as well as hematologic tumors. So, which means we really need to know about the ADC to manage toxicities. That’s why, and then the ADC structure has a very characteristic feature. It components three antibodies and payload and also linker...
so now it’s the era of ADC. Since the first developed ADC in 2000, and then already it passed 20 more years, during that time, ADC is a kind of a backbone of treatment for solid tumor as well as hematologic tumors. So, which means we really need to know about the ADC to manage toxicities. That’s why, and then the ADC structure has a very characteristic feature. It components three antibodies and payload and also linker. So, very special structure and toxicity determinant composed of these three structures kind of interaction. That’s what we need to know for the toxicity of ADC for every oncologist.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
